Biomarkers in acute respiratory distress syndrome

Current Opinion in Critical Care

Volumn 20, Issue 1, 2014, Pages 47-55

  Binnie, Alexandra ^a   Tsang, Jennifer L Y ^b   Dos Santos, Claudia C ^c,d  

^a ST JOSEPH S HEALTH CENTRE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

acute lung injury; acute respiratory distress syndrome; biomarkers; ventilator induced associated lung injury

Indexed keywords

ARTIFICIAL VENTILATION; BLOOD GAS; DYNAMIC STRAIN; HUMAN; INJURY SEVERITY; LUNG CAPILLARY PRESSURE; LUNG HEMODYNAMICS; NONHUMAN; PATHOGENESIS; POSITIVE END EXPIRATORY PRESSURE; REVIEW; RISK ASSESSMENT; STATIC STRAIN; STRESS; STRUCTURE ANALYSIS; TIDAL VOLUME; TOTAL LUNG CAPACITY; VENTILATOR INDUCED LUNG INJURY; VISCOELASTICITY;

ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MUCIN-1; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESEARCH; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTILATOR-INDUCED LUNG INJURY; VESICULAR TRANSPORT PROTEINS; VON WILLEBRAND FACTOR;

EID: 84895069834     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0000000000000048     Document Type: Review

References (97)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89-95.
2. World Health Organization. Biomarkers in risk assessment: validity and validation (EHC 222, 2001) [Internet]. inchem.org [no date], [no volume].
3. Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Statist Med 2012; 31:2973-2984.
4. van der Heijden M, van Nieuw Amerongen GP, Koolwijk P, et al. Angiopoietin- 2, permeability oedema, occurrence and severity of ALI/ARDS in septic and nonseptic critically ill patients. Thorax 2008; 63:903-909.
5. Gallagher DC, Parikh SM, Balonov K, et al. Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome. Shock 2008; 29:656-661.
6. Kranidioti H, Orfanos SE, Vaki I, et al. Angiopoietin-2 is increased in septic shock: evidence for the existence of a circulating factor stimulating its release from human monocytes. Immunol Lett 2009; 125:65-71.
7. Agrawal A, Matthay MA, Kangelaris KN, et al. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am J Respir Crit Care Med 2013; 187:736-742.
8. Wada T, Jesmin S, Gando S, et al. The role of angiogenic factors and their soluble receptors in acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) associated with critical illness. J Inflamm 2013; 10:1-11.
9. Calfee CS, Gallagher D, Abbott J, et al., the NHLBI ARDS Network. Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance. Crit Care Med 2012; 40:1731-1737.
10. Determann RM, Royakkers AANM, Haitsma JJ, et al. Plasma levels of surfactant protein D and KL-6 for evaluation of lung injury in critically ill mechanically ventilated patients. BMC Pulm Med 2010; 10:6.
11. Determann RM, Millo JL, Waddy S, et al. Plasma CC16 levels are associated with development of ALI/ARDS in patients with ventilator-Associated pneumonia: a retrospective observational study. BMC Pulm Med 2009; 9:49.
12. Geerts L, Jorens PG, Willems J, et al. Natural inhibitors of neutrophil function in acute respiratory distress syndrome. Crit Care Med 2001; 29:1920-1924.
13. Lesur O, Langevin S, Berthiaume Y, et al. Outcome value of Clara cell protein in serum of patients with acute respiratory distress syndrome. Intensive Care Med 2006; 32:1167-1174.
14. Kropski JA. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. Chest 2009; 135:1440.
15. Terragni PP, Del Sorbo L, Mascia L, et al. Tidal volume lower than 6 ml/kg enhances lung protection: role of extracorporeal carbon dioxide removal. Anesthesiology 2009; 111:826-835.
16. Meduri GU, Headley S, Kohler G, et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995; 107:1062-1073.
17. Nakamura T, Sato E, Fujiwara N, et al. Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome. Clin Biochem 2011; 44:601-604.
18. Stuber F, Wrigge H, Schroeder S, et al. Kinetic and reversibility of mechanical ventilation-Associated pulmonary and systemic inflammatory response in patients with acute lung injury. Intensive Care Med 2002; 28:834-841.
19. Ranieri VM, Suter PM, Tortorella C, et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. J Am Med Assoc 1999; 282:54-61.
20. Ware LB, Koyama T, Billheimer DD, et al. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 2010; 137:288-296.
21. McClintock D, Zhuo H, Wickersham N, et al. Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury. Crit Care 2008; 12:R41.
22. Brower RG, Lanken PN, MacIntyre N, et al. Higher versus lower positive endexpiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004; 351:327.
23. Diehl JL, Coolen N, Faisy C, et al. Growth-Arrest-specific 6 (GAS6) protein in ARDS patients: determination of plasma levels and influence of PEEP setting. Respir Care 2013; 58:1886-1891.
24. Calfee CS, Ware LB, Glidden DV, et al. National Heart, Blood, and Lung Institute Acute Respiratory Distress Syndrome Network: use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury. Crit Care Med 2011; 39:711-717.
25. Kondo T, Hattori N, Ishikawa N, et al. KL-6 concentration in pulmonary epithelial lining fluid is a useful prognostic indicator in patients with acute respiratory distress syndrome. Respir Res 2011; 12:32.
26. Nathani N, Perkins GD, Tunnicliffe W, et al. Kerbs von Lungren 6 antigen is a marker of alveolar inflammation but not of infection in patients with acute respiratory distress syndrome. Crit Care 2008; 12:R12.
27. Sato H, Callister MEJ, Mumby S, et al. KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome. Eur Respir J 2004; 23:142-145.
28. Moalli R, Doyle JM, Tahhan HR, et al. Fibrinolysis in critically ill patients. Am Rev Respir Dis 1989; 140:287-293.
29. Prabhakaran P, Ware LB, White KE, et al. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285:L20-L28.
30. Jalkanen V, Yang R, Linko R, et al. FINNALI Study Group: SuPAR and PAI-1 in critically ill, mechanically ventilated patients. Intensive Care Med 2013; 39:489-496.
31. Ware LB, Matthay MA, Parsons PE, et al. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007; 35:1821-1828.
32. Bertozzi P, Astedt B, Zenzius L, et al. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 1990; 322:890-897.
33. Ware LB, Fang X, Matthay MA. Protein Cand thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285:L514-L521.
34. Calfee CS, Eisner MD, Parsons PE, et al. NHLBI Acute Respiratory Distress Syndrome Clinical Trials Network: soluble intercellular adhesion molecule-1 and clinical outcomes in patients with acute lung injury. Intensive Care Med 2009; 35:248-257.
35. Cepkova M, Brady S, Sapru A, et al. Biological markers of lung injury before and after the institution of positive pressure ventilation in patients with acute lung injury. Crit Care 2006; 10:R126.
36. Uchida T, Shirasawa M, Ware LB, et al. Receptor for advanced glycation endproducts is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med 2006; 173:1008-1015.
37. Mauri T, Masson S, Pradella A, et al. Elevated plasma and alveolar levels of soluble receptor for advanced glycation endproducts are associated with severity of lung dysfunction in ARDS patients. Tohoku J Exp Med 2010; 222:105-112.
38. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055-2064.
39. Bowler RP. Proteomic analysis of pulmonary edema fluid and plasma in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004; 286:L1095-L1104.
40. Pison U, Obertacke U, Seeger W, Hawgood S. Surfactant protein A (SP-A) is decreased in acute parenchymal lung injury associated with polytrauma. Eur J Clin Invest 1992; 22:712-718.
41. Doyle IR, Nicholas TE, Bersten AD. Serum surfactant protein-A levels in patients with acute cardiogenic pulmonary edema and adult respiratory distress syndrome. Am J Respir Crit Care Med 1995; 152:307-317.
42. Veldhuizen RA, McCaig LA, Akino T, Lewis JF. Pulmonary surfactant subfractions in patients with the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995; 152:1867-1871.
43. Gu? nther A, Siebert C, Schmidt R, et al. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996; 153:176-184.
44. Shimura S, Masuda T, Takishima T, Shirato K. Surfactant apoprotein-A concentration in airway secretions for the detection of pulmonary oedema. Eur Respir J 1996; 9:2525-2530.
45. Gregory TJ, Longmore WJ, Moxley MA, et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991; 88:1976-1981.
46. Greene KE, Wright JR, Steinberg KP, et al. Serial changes in surfactantassociated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 1999; 160:1843-1850.
47. Bersten AD, Hunt T, Nicholas TE, Doyle IR. Elevated plasma surfactant protein-B predicts development of acute respiratory distress syndrome in patients with acute respiratory failure. Am J Respir Crit Care Med 2001; 164:648-652.
48. Schmidt R, Steinhilber W, Ruppert C, et al. An ELISA technique for quantification of surfactant apoprotein (SP)-C in bronchoalveolar lavage fluid. Am J Respir Crit Care Med 2002; 165:470-474.
49. Abadie Y, Bregeon F, Papazian L, et al. Decreased VEGF concentration in lung tissue and vascular injury during ARDS. Eur Respir J 2005; 25:139- 146.
50. Doyle IR, Bersten AD, Nicholas TE. Surfactant proteins-A and -B are elevated in plasma of patients with acute respiratory failure. Am J Respir Crit Care Med 1997; 156:1217-1229.
51. Schmidt R, Markart P, Ruppert C, et al. Time-dependent changes in pulmonary surfactant function and composition in acute respiratory distress syndrome due to pneumonia or aspiration. Respir Res 2007; 8:55.
52. Eisner MD, Parsons P, Matthay MA, et al. Acute Respiratory Distress Syndrome Network: plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax 2003; 58:983-988.
53. Azamfirei L, Gurzu S, Solomon R, et al. Vascular endothelial growth factor: a possible mediator of endothelial activation in acute respiratory distress syndrome. Minerva Anestesiol 2010; 76:609-616.
54. Thickett DR, Armstrong L, Christie SJ, Millar AB. Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 164:1601- 1605.
55. Medford ARL, Douglas SK, Godinho SIH, et al. Vascular endothelial growth factor (VEGF) isoform expression and activity in human and murine lung injury. Respir Res 2009; 10:27.
56. Koh H, Tasaka S, Hasegawa A, et al. Vascular endothelial growth factor in epithelial lining fluid of patients with acute respiratory distress syndrome. Respirology 2008; 13:281-284.
57. Maitre B, Boussat S, Jean D, et al. Vascular endothelial growth factor synthesis in the acute phase of experimental and clinical lung injury. Eur Respir J 2001; 18:100-106.
58. Thickett DR, Armstrong L, Millar AB. A role for vascular endothelial growth factor in acute and resolving lung injury. Am J Respir Crit Care Med 2002; 166:1332-1337.
59. Phua J, Badia JR, Adhikari NKJ, et al. Has mortality from acute respiratory distress syndrome decreased over time? Am J Respir Crit Care Med 2009; 179:220-227.
60. Rubenfeld GD, Herridge MS. Epidemiology and outcomes of acute lung injury. Chest 2007; 131:554-562.
61. Herridge MS, Tansey CM, Matte A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med 2011; 364:1293-1304.
62. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967; 2:319-323.
63. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149:818- 824.
64. The ARDS Definition Task Force. Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA 2012; 307:2526- 2533.
65. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest 2012; 122:2731-2740.
66. Pen?uelas O, Aramburu JA, Frutos-Vivar F, Esteban A. Pathology of acute lung injury and acute respiratory distress syndrome: a clinical-pathological correlation. Clin Chest Med 2006; 27:; 571-8
67. Esteban A, Fernandez-Segoviano P, Frutos-Vivar F, et al. Comparison of clinical criteria for the acute respiratory distress syndrome with autopsy findings. Ann Intern Med 2004; 141:440-445.
68. Sarmiento X, Guardiola JJ, Almirall J, et al. Discrepancy between clinical criteria for diagnosing acute respiratory distress syndrome secondary to community acquired pneumonia with autopsy findings of diffuse alveolar damage. Respir Med 2011; 105:1170-1175.
69. Ferguson ND, Frutos-Vivar F, Esteban A, et al. Acute respiratory distress syndrome: underrecognition by clinicians and diagnostic accuracy of three clinical definitions. Crit Care Med 2005; 33:2228-2234.
70. Thille AW, Esteban A, Fernandez-Segoviano P, et al. Comparison of the Berlin definition for acute respiratory distress syndrome with autopsy. Am J Respir Crit Care Med 2013; 187:761-767.
71. Suter PM, Suter S, Girardin E, et al. High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis 1992; 145:1016-1022.
72. Siler TM, Swierkosz JE, Hyers TM, et al. Immunoreactive interleukin-1 in bronchoalveolar lavage fluid of high-risk patients and patients with the adult respiratory distress syndrome. Exp Lung Res 1989; 15:881-894.
73. Makabe H, Kojika M, Takahashi G, et al. Interleukin-18 levels reflect the longterm prognosis of acute lung injury and acute respiratory distress syndrome. J Anesth 2012; 26:658-663.
74. Roumen RM, Hendriks T, van der Ven-Jongekrijg J, et al. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993; 218:769-776.
75. Meade P, Shoemaker WC, Donnelly TJ, et al. Temporal patterns of hemodynamics, oxygen transport, cytokine activity, and complement activity in the development of adult respiratory distress syndrome after severe injury. J Trauma Acute Care Surg 1994; 36:651-657.
76. Donnelly TJ, Meade P, Jagels M, et al. Cytokine, complement, and endotoxin profiles associated with the development of the adult respiratory distress syndrome after severe injury. Crit Care Med 1994; 22:768- 776.
77. ARDS Net. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342:1301-1308.
78. Xing K, Murthy S, Liles WC, Singh JM. Clinical utility of biomarkers of endothelial activation in sepsis-A systematic review. Crit Care 2012; 16:R7. An excellent review of biomarkers in sepsis, including Ang-2.
79. Cornet AD, Hofstra JJ, Vlaar AP, et al. Activated protein C attenuates pulmonary coagulopathy in patients with acute respiratory distress syndrome. J Thromb Haemost 2013; 11:894-901.
80. Perez-Gil J, Weaver TE. Pulmonary surfactant pathophysiology: current models and open questions. Physiology 2010; 25:132-141.
81. Pires-Neto RC, Morales MMB, Lancas T, et al. Expression of acute-phase cytokines, surfactant proteins, andepithelial apoptosis insmall airways of human acute respiratory distress syndrome. J Crit Care 2013; 28:111; e9-111.e15.
82. Baker CS, Evans TW, Randle BJ, Haslam PL. Damage to surfactant-specific protein in acute respiratory distress syndrome. Lancet 1999; 353:1232-1237.
83. Duffett M, Choong K, Ng V, et al. Surfactant therapy for acute respiratory failure in children: a systematic review and meta-Analysis. Crit Care 2007; 11:R66.
84. Davidson WJ, Dorscheid D, Spragg R, et al. Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-Analysis. Crit Care 2006; 10:R41.
85. Guo WA, Knight PR, Raghavendran K. The receptor for advanced glycation end products and acute lung injury/acute respiratory distress syndrome. Intensive Care Med 2012; 38:1588-1598.
86. Narvaez-Rivera RM, Rendon A, Salinas-Carmona MC, Rosas-Taraco AG. Soluble RAGE as a severity marker in community acquired pneumonia associated sepsis. BMC Infect Dis 2012; 12:15.
87. Fremont RD, Koyama T, Calfee CS, et al. Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis. J Trauma 2010; 68:1121-1127.
88. Medford ARL, Godinho SIH, Keen LJ, et al. Relationship between vascular endothelial growth factor 936 genotype and plasma/epithelial lining fluid vascular endothelial growth factor protein levels in patients with and at risk for ARDS. Chest 2009; 136:457-464.
89. Modig J, Bagge L. Specific coagulation and fibrinolysis tests as biochemical markers in traumatic-induced adult respiratory distress syndrome. Resuscitation 1986; 13:87-95.
90. Rubin DB, Wiener-Kronish JP, Murray JF, et al. Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest 1990; 86:474-480.
91. Carvalho AC, Bellman SM, Saullo VJ, et al. Altered factor VIII in acute respiratory failure. N Engl J Med 1982; 307:1113-1119.
92. Moss M, Ackerson L, Gillespie MK, et al. von Willebrand factor antigen levels are not predictive for the adult respiratory distress syndrome. Am J Respir Crit Care Med 1995; 151:15-20.
93. Ware LB, Eisner MD, Thompson BT, et al. Significance of Von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med 2004; 170:766-772.
94. van der Heijden M, van Nieuw Amerongen GP, Chedamni S, et al. The angiopoietin-Tie2 system as a therapeutic target in sepsis and acute lung injury. Expert Opin Ther Targets 2009; 13:39-53.
95. Liles WC. Is angiopoietin-2 the key piece in the sepsis puzzle?-. Crit Care Med 2012; 40:3100-3101.
96. Su L, Zhai R, Sheu C-C, et al. Genetic variants in the angiopoietin-2 gene are associated with increased risk of ARDS. Intensive Care Med 2009; 35:1024-1030.
97. Meyer NJ, Li M, Feng R, et al. ANGPT2 genetic variant is associated with trauma-Associated acute lung injury and altered plasma angiopoietin-2 isoform ratio. Am J Respir Crit Care Med 2011; 183:1344-1353.